This article is more than 5 years old. Information may no longer be current.
FDA grants fast track designation to balixafortide for metastatic breast cancer
Click Here to Manage Email Alerts
The FDA granted fast track designation to balixafortide in combination with eribulin for the treatment of patients with HER-2-negative metastatic breast cancer who failed at least two prior chemotherapy regimens.
Balixafortide (POL6326, Polyphor) is a highly selective CXCR4 antagonist.
The combination of balixafortide and eribulin (Halaven, Eisai) demonstrated activity in a phase 1b proof-of-concept trial that included patients with metastatic breast cancer, according to a Polyphor-issued press release.
“We have already identified a development path for balixafortide with input from the FDA to conduct a single pivotal study in this indication,” Giacomo Di Nepi, CEO of Polyphor, said in the release. “Fast track designation is another positive step for the development of balixafortide and a recognition of the need for better treatments for this group of patients.”
The pivotal trial will evaluate balixafortide in combination with eribulin for the treatment of patients with HER-2-negative breast cancer who have received at least two prior chemotherapeutic regimens in the metastatic setting.